Our mission is to use scientific innovation to improve the lives of people, their families and the communities we serve. We are deeply committed to making a difference in the lives of people living with serious rare conditions.
Our strategy is to target the biological root causes of the serious rare conditions we seek to treat and improve the quality of life for those affected.
Founded in 2014, Therachon’s first investigational program focused on achondroplasia. Building on our commitment to address the biological roots of serious conditions with high unmet need, we added a product candidate for short bowel syndrome (intestinal failure) to our portfolio in late 2018.
From the start, our development program has been characterized by well-validated targets, well-characterized patient populations and the potential for our therapies to be best-in-disease.